Literature DB >> 30562268

The association between endogenous opioid function and morphine responsiveness: a moderating role for endocannabinoids.

Stephen Bruehl1, John W Burns2, Amanda Morgan3, Kelli Koltyn4, Rajnish Gupta1, Asokumar Buvanendran5, David Edwards1, Melissa Chont1, Philip J Kingsley6,7, Larry Marnett6, Amanda Stone1, Sachin Patel3.   

Abstract

We sought to replicate previous findings that low endogenous opioid (EO) function predicts greater morphine analgesia and extended these findings by examining whether circulating endocannabinoids and related lipids moderate EO-related predictive effects. Individuals with chronic low-back pain (n = 46) provided blood samples for endocannabinoid analyses, then underwent separate identical laboratory sessions under 3 drug conditions: saline placebo, intravenous (i.v.) naloxone (opioid antagonist; 12-mg total), and i.v. morphine (0.09-mg/kg total). During each session, participants rated low-back pain intensity, evoked heat pain intensity, and nonpain subjective effects 4 times in sequence after incremental drug dosing. Mean morphine effects (morphine-placebo difference) and opioid blockade effects (naloxone-placebo difference; to index EO function) for each primary outcome (low-back pain intensity, evoked heat pain intensity, and nonpain subjective effects) were derived by averaging across the 4 incremental doses. The association between EO function and morphine-induced back pain relief was significantly moderated by endocannabinoids [2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA)]. Lower EO function predicted greater morphine analgesia only for those with relatively lower endocannabinoids. Endocannabinoids also significantly moderated EO effects on morphine-related changes in visual analog scale-evoked pain intensity (2-AG), drug liking (AEA and 2-AG), and desire to take again (AEA and 2-AG). In the absence of significant interactions, lower EO function predicted significantly greater morphine analgesia (as in past work) and euphoria. Results indicate that EO effects on analgesic and subjective responses to opioid medications are greatest when endocannabinoid levels are low. These findings may help guide development of mechanism-based predictors for personalized pain medicine algorithms.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30562268      PMCID: PMC6377294          DOI: 10.1097/j.pain.0000000000001447

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  52 in total

1.  A flood of opioids, a rising tide of deaths.

Authors:  Susan Okie
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 91.245

2.  Parental history of chronic pain may be associated with impairments in endogenous opioid analgesic systems.

Authors:  Stephen Bruehl; Ok Yung Chung
Journal:  Pain       Date:  2006-05-24       Impact factor: 6.961

3.  Self-reported cumulative medical opioid exposure and subjective responses on first use of opioids predict analgesic and subjective responses to placebo-controlled opioid administration.

Authors:  Stephen Bruehl; Amanda L Stone; Cassandra Palmer; David A Edwards; Asokumar Buvanendran; Rajnish Gupta; Melissa Chont; Mary Kennedy; John W Burns
Journal:  Reg Anesth Pain Med       Date:  2019-01       Impact factor: 6.288

4.  Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children.

Authors:  Vidya Chidambaran; Valentina Pilipenko; Kristie Spruance; Raja Venkatasubramanian; Jing Niu; Tsuyoshi Fukuda; Tomoyuki Mizuno; Kejian Zhang; Kenneth Kaufman; Alexander A Vinks; Lisa J Martin; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2016-12-15       Impact factor: 2.533

5.  Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy.

Authors:  David Yarnitsky; Michal Granot; Hadas Nahman-Averbuch; Mogher Khamaisi; Yelena Granovsky
Journal:  Pain       Date:  2012-04-03       Impact factor: 6.961

Review 6.  Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies.

Authors:  Marieke Niesters; Albert Dahan; Benjamin Kest; James Zacny; Theo Stijnen; Leon Aarts; Elise Sarton
Journal:  Pain       Date:  2010-08-09       Impact factor: 6.961

7.  Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer.

Authors:  Kristiina Cajanus; Emil J Holmström; Maija Wessman; Verneri Anttila; Mari A Kaunisto; Eija Kalso
Journal:  Pain       Date:  2016-02       Impact factor: 6.961

8.  The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.

Authors:  D da Fonseca Pacheco; A Klein; A de Castro Perez; C M da Fonseca Pacheco; J N de Francischi; I D G Duarte
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

9.  Abuse liability of oxycodone as a function of pain and drug use history.

Authors:  S D Comer; M A Sullivan; S K Vosburg; W J Kowalczyk; J Houser
Journal:  Drug Alcohol Depend       Date:  2010-01-15       Impact factor: 4.492

10.  Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Elizabeth Crane; Jinhee Lee; Christopher M Jones
Journal:  Ann Intern Med       Date:  2017-08-01       Impact factor: 25.391

View more
  5 in total

Review 1.  A Theoretical Endogenous Opioid Neurobiological Framework for Co-occurring Pain, Trauma, and Non-suicidal Self-injury.

Authors:  Benjamin N Johnson; Lindsey C McKernan; Stephen Bruehl
Journal:  Curr Pain Headache Rep       Date:  2022-04-05

Review 2.  Toward Composite Pain Biomarkers of Neuropathic Pain-Focus on Peripheral Neuropathic Pain.

Authors:  Monica M Diaz; Jacob Caylor; Irina Strigo; Imanuel Lerman; Brook Henry; Eduardo Lopez; Mark S Wallace; Ronald J Ellis; Alan N Simmons; John R Keltner
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-11

3.  Endogenous anandamide and self-reported pain are significantly reduced after a 2-week multimodal treatment with and without radon therapy in patients with knee osteoarthritis: a pilot study.

Authors:  M Gaisberger; J Fuchs; M Riedl; S Edtinger; R Reischl; G Grasmann; B Hölzl; F Landauer; H Dobias; F Eckstein; M Offenbächer; M Ritter; M Winklmayr
Journal:  Int J Biometeorol       Date:  2021-03-01       Impact factor: 3.787

4.  Does aerobic exercise training alter responses to opioid analgesics in individuals with chronic low back pain? A randomized controlled trial.

Authors:  Stephen Bruehl; John W Burns; Kelli Koltyn; Rajnish Gupta; Asokumar Buvanendran; David Edwards; Melissa Chont; Yung Hsuan Wu; Amanda Stone
Journal:  Pain       Date:  2021-08-01       Impact factor: 7.926

5.  Greater Conditioned Pain Modulation Is Associated With Enhanced Morphine Analgesia in Healthy Individuals and Patients With Chronic Low Back Pain.

Authors:  Stephen Bruehl; Christopher R France; Amanda L Stone; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; John W Burns
Journal:  Clin J Pain       Date:  2021-01       Impact factor: 3.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.